There are now considerable clinical trial data to support the use of b-adrenoceptor blockers in patients with chronic heart failure due to systolic left ventricular dysfunction. Increases in ejection fraction, improved well-being as judged by both patient and physician and reduced progression of ventricular dysfunction have been demonstrated. From meta-analyses of available trial data, a mortality reduction of approximately 30% is obtained when these drugs are added to standard heart failure therapies. Furthermore, reductions in cardiovascular morbidity associated with decreased hospitalization rates suggest pharmacoeconomic benefits with these agents.
Introduction heart failure and practical issues regarding the administration of these agents to these patients. There has been considerable interest in recent years regarding the use of b-adrenoceptor blockers in the management of patients with chronic heart failure. The use of b-adrenoceptor Role of the sympathetic nervous system in heart blockers as additional therapy to standard treatment for failure symptomatic systolic left ventricular dysfunction may come as a surprise to many clinicians, as this is the very group of Heart failure is characterized by activation of a number of neurohormonal vasoconstrictor systems [2] [3] [4] including the drugs long regarded as contra-indicated in the management of this condition. However, the rationale for their use is sympathetic nervous system, the renin-angiotensin system, vasopressin, and more recently the endothelial-derived based on the increasing body of knowledge regarding the pathophysiology of heart failure, in particular the adverse peptide, endothelin-1. This neurohormonal activation can be viewed as a compensatory response to the reduction in consequences on disease progression of the neurohormonal vasoconstrictor activation that accompanies this condition.
cardiac output and systemic blood pressure that accompanies systolic ventricular dysfunction. Why do we need new drugs for heart failure? Standard modern day pharmacological management of this condition b-adrenoceptor agonism (Figure 1 ) activates regulatory G proteins to increase intracellular cyclic adenosine monophosincludes an ACE inhibitor, digoxin and a diuretic. Whilst ACE inhibitors have resulted in significant improvements in phate (AMP) via adenylate cyclase [5] stimulation. Increased cyclic AMP stimulates protein kinase, which in turn patient clinical status and mortality outcomes, these benefits are relatively modest. For example, in the CONSENSUS phosphorylates calcium channels leading to influx of intracellular calcium and enhancement of coupling of actin study [1] there was a significant mortality reduction observed with enalapril in comparison with placebo when added to and myosin filaments, resulting in an inotropic effect. Whilst there is generalized sympathetic activation in heart digoxin and diuretic. However, even in the enalapril-treated group, there was a 47% mortality at the end of 12 months failure, noradrenaline spillover is particularly increased in heart and kidneys [6] . As a consequence of the chronic in these New York Heart Association (NYHA) Class IV (severely symptomatic) patients. Hence, the need for catecholamine excess that accompanies this activation, there is depletion of catecholamines from storage vesicles in additional therapies in these patients is great.
This review seeks to summarize current knowledge cardiac sympathetic nerve terminals [7] , downregulation (decreased density) of b-adrenoceptors on myocardial cells regarding the use of b-adrenoceptor blockers in this clinical setting. In order to address this topic in a clinically relevant and uncoupling of the receptor from adenylate cyclase [5] .
In the short-term, the sympathetic activation that manner, the following issues will be discussed: the known adverse effects of chronic sympathetic activation in heart accompanies heart failure is an important compensatory mechanism providing inotropic support and maintaining failure, the theoretical benefits of blockade of this system, cardiac output; indeed, that is the rationale for the use of sympathomimetic amines in patients with acutely decompen- this sympathetic activation may be deleterious, thus providing toxic effects of catecholamines on the myocardium is associated with improved clinical status and survival outcomes the rationale for use of b-adrenoceptor blocking agents in this setting. There are several lines of evidence to support in these patients. the conclusion that long-term sympathetic activation is detrimental in heart failure and contributes to disease Rationale for adrenergic blockade in patients with progression and adverse clinical outcomes.
chronic heart failure
The preceding mechanistic and clinical data regarding longEvidence from mechanistic studies term sympathetic activation in chronic heart failure strongly support a therapeutic role for b-adrenoceptor blockers in Possible detrimental effects of long-term sympathetic activation derived from mechanistic studies in chronic heart this condition. Theoretical benefits of b-adrenoceptor blockers include direct myocardial protection from the toxic failure include direct myocardial toxicity secondary to longterm catecholamine excess [8] , requirement for increased effects of catecholamines, reduction in stimulation of other neurohormonal vasoconstrictor systems, blockade of the myocardial oxygen consumption [9], myocardial badrenoceptor down regulation [5] , impaired myocardial proarrhythmic effects of catecholamines and anti-ischaemic effects via increased coronary blood flow during diastole, function secondary to tachycardia, reduction in threshold for arrhythmogenesis [10] and activation of other vasoconand reduced myocardial oxygen demand. It has also been proposed that restoration of bstrictor systems such as the renin-angiotensin system. adrenoceptor density and receptor-adenylate cyclase coupling with the use of these drugs may be a potential mechanism Evidence from clinical studies for their beneficial effects. Myocardial b-adrenoceptor downregulation and receptor-cyclase uncoupling in heart There are also a number of lines of evidence supporting the deleterious effects of chronic sympathetic activation derived failure may limit contractile function [5, 14, 15] and drugs such as metoprolol [16] have been demonstrated to increase from clinical studies.
It has long been observed that patients with diseases b-adrenoceptor density in this setting. However, at least two other b-adrenoceptor blocking drugs have been demonassociated with chronic catecholamine excess e.g pheochromocytoma [11] present with myocardial disease indistinguishstrated to produce significant clinical benefits in this condition (carvedilol, bucindolol) and do not appear (at least able from that of dilated cardiomyopathy.
Drugs that augment the effects of catecholamines on the from one laboratory) to be associated with b-adrenoceptor up-regulation or restoration of receptor-cyclase coupling myocardium such as b-adrenoceptor agonists [12] or type III phosphodiesterase [13] inhibitors are associated with adverse
[17] (see later). Thus, although some b-adrenoceptor blockers do cause up-regulation of b-adrenoceptors, this is unlikely mortality outcomes. This was perhaps best demonstrated in the PROMISE study [13] with long-term oral use of the to be the mechanism of benefit of this group of drugs overall. phosphodiesterase inhibitor, milrinone, associated with significantly impaired survival. Similar outcomes were associEffect of b-adrenoceptor blockers on clinical status in ated with the partial b-adrenoceptor agonist, xamoterol [12] .
patients with chronic heart failure In contrast to these dismal results with long term oral treatment, milrinone remains a useful short-term intravenous
The intense interest in b-adrenoceptor blockers as a therapeutic modality in the management of chronic therapy providing inotropic support to the failing myocardium in decompensated heart failure.
heart failure is a result of 20 years of cumulative clinical experience, beginning with the pioneering clinical obserFinally, the accumulating evidence from studies of b-adrenoceptor blockers themselves in heart failure support vations of Swedish [18] [19] [20] and other [21, 22] investigators. These early studies were often uncontrolled and involved the underlying rationale for their use: that blockade of the administration of the drugs for only short periods of time, rationale for the use of these drugs is that the vasodilator component of the drug helps overcome the initial negative but the clinical experience and data obtained from these trials has subsequently proven invaluable, leading to larger inotropic component of the b-adrenoceptor blockade, thus improving tolerability of the drug during the initiation and placebo-controlled studies and more widespread clinical use of these drugs.
up-titration phase. Use of such drugs has improved patient tolerability such that only 5-7% of these patients could not Short term use of b-adrenoceptor blockers in these early studies [21, 22] was found to result in neutral or adverse tolerate the initiation phase of these studies. Thus, tolerability of initiation of therapy with b-adrenoceptor blockers is clinical outcomes and led many investigators to abandon this therapeutic approach. However, it is now understood that, comparable with that seen with initiation of ACE inhibitors in heart failure patients in the early 1980s. in the context of recovery of the myocardium from chronic catecholamine stimulation, studies of at least 3 months
The beneficial clinical effects observed with b-adrenoceptor blockers in heart failure in single-centre studies has duration are required to demonstrate clinical benefit with these drugs. Early studies were also important in establishing led to the more widespread evaluation of these drugs. A series of multi-centre clinical studies has been conducted the need for commencement of b-adrenoceptor blocker therapy at extremely low doses to avoid sudden interference [34] [35] [36] [37] [38] [39] , predominantly with the b-adrenoceptor blockervasodilator carvedilol, but additional multi-centre studies are with the inotropic support provided to the failing myocardium by the increased sympathetic activity that accompanies ongoing with other drugs. The carvedilol study program [35] [36] [37] [38] [39] addressed multiple heart failure.
Since these early trials, a number of long term doublequestions regarding clinical efficacy of this drug in heart failure: use in delaying progression of heart failure, clinical blind, placebo-controlled studies of b-adrenoceptor blockers have assessed clinical status in patients with chronic heart utility in patients with moderate to severe heart failure and whether a clinical dose-response relationship existed. Findings failure [23] [24] [25] [26] [27] [28] [29] [30] [31] (Table 1 ). These studies have demonstrated consistent improvements in ejection fraction, usually are summarized in Table 2 . The overall findings were concordant with those of the previous single-centre studies with accompanied by improved patient well-being, but with variable effects on exercise tolerance. The lack of consistent the drug. Carvedilol significantly improved left ventricular ejection fraction, NYHA functional class and physician and benefit of b-adrenoceptor blockers on exercise tolerance is a feature of therapy with this drug class and relates to the patient global assessment of heart failure status. Improvements in left ventricular function were found to be dose-dependent, heart rate-limiting effects of b-adrenoceptor blockade during exercise. Heart rate is one of the factors that determines the greatest benefits being seen in those patients randomized to receive the highest dose of the drug [38] . maximal exercise capacity (VO 2 max.) and as such it is not surprising that b-adrenoceptor blockers do not lead to Retardation of progression of disease with carvedilol was also noted in the Australian New Zealand Heart Failure increases in VO 2 max. despite the haemodynamic improvements that accompany use of these drugs. These studies also Study [39] , where a reduction in left ventricular chamber size was observed in mild heart failure patients treated with demonstrated that b-adrenoceptor blockers inhibit other neurohormonal systems activated in chronic heart failure, b-adrenoceptor blocker, indicating restoration of ventricular contour towards normal. This finding provides strong a priori such as the renin-angiotensin [27] system and endothelin-1 [32] , as well as restoring parasympathetic activity [33] , evidence that excess catecholamines are important in the ventricular remodelling process in heart failure and impaired in this condition.
The placebo-controlled studies also established the safety b-adrenoceptor blockers can interfere with this remodelling in a clinically significant manner. However, significant and tolerability of b-adrenoceptor blockers when introduced at low doses to heart failure patients. Many of these studies improvements in New York Heart Association class were not seen in this very mild group of patients, 30% of whom were conducted with drugs that also possess vasodilator properties in addition to their b-adrenoceptor blocking effects.
were already NYHA class I (i.e. asymptomatic) at time of entry into the study. Such agents include carvedilol, bucindolol and nebivolol. The Table 1 Single centre studies of randomized controlled trials of clinical efficacy of long-term (≥3 months) therapy with b-adrenoceptor blocking agents in patients with congestive heart failure. (D=change from baseline; LVEF=left ventricular ejection fraction; submax.= submaximal exercise testing, e.g. 6 min corridor walk test). patients as those sub-groups with the greatest mortality Effect of b-adrenoceptor blockade on morbidity and benefit to be obtained from the use of these agents. mortality in patients with chronic heart failure More recently, the US Multi-centre Carvedilol Study Program was terminated early by their Data Safety Because b-adrenoceptor blockers have the potential to make patients feel worse in the short-term before long-term
Monitoring Board because of a highly significant 65% mortality reduction observed with carvedilol in comparison clinical improvements are obtained with these drugs, many physicians may be reluctant to provide their patients with with placebo when added to standard therapy [44] . Unlike the CIBIS study, the magnitude of this benefit was similar this therapy in the absence of an accompanying morbidity and mortality benefit. This is a reasonable approach to drug in patients with mild or severe symptoms, and where idiopathic dilated or ischaemic cardiomyopathy was the therapy in heart failure given the poor track record in recent years of many drugs that have improved patient symptoms aetiology of heart failure. The mortality benefit observed with carvedilol in the US and well-being only to be subsequently found to be associated with an adverse effect on mortality (e.g. flosequi-
Multicentre Carvedilol Study Program, like that seen on left ventricular function, appears to be dose-dependent [38] . nan [40] , milrinone [13], vesnarinone [57] ).
This divergence of improved patients well-being and The finding of a dose relationship provides scientific underpinning to the mortality benefits observed with the adverse effects on mortality may also be true of b-adrenoceptor blockers. However many of the theoretical effects of drug, but is also of major practical clinical significance as it indicates the need to achieve the target dose of b-adrenoceptor blockers indicate that they would provide mortality benefits. Chronic sympathetic activation is associated b-adrenoceptor blocker to maximise mortality benefits in these patients. This will be discussed further in the section with adverse mortality outcomes in heart failure. Patients with the highest plasma levels of noradrenaline (a crude 'Approach to management of the heart failure patient with b-adrenoceptor blockers'. marker of sympathetic activation) have the most adverse mortality outcomes [41] . As sympathetic activation is also a Whilst the mortality benefits observed in the US Multicentre Carvedilol Study Program were substantial, only marker of disease severity [42] , the mortality association may simply reflect patients with the most advanced disease having a small number of deaths were recorded in the overall program (53 in total), leading some observers to conclude the greatest mortality. Chronic sympathetic stimulation is associated with proarrhythmia, direct trophic and toxic effects that a definitive mortality effect with b-adrenoceptor blockers had not been adequately demonstrated. Although on the myocardium and activation of other neurohormonal systems, all of which may independently lead to adverse there is some merit to this argument, it is also true that the mortality effects were observed with very tight confidence mortality outcomes. Thus, it would be reasonably anticipated that use of these drugs should confer beneficial effects on intervals, even in sub-group analyses, indicating that these results were most unlikely to have occurred by chance. mortality providing a powerful rationale for prescribing such drugs in these patients.
Even if the 'real' effect of the drug on mortality was half that observed, this still represents a highly significant clinical There have thus far been three major multi-centre mortality studies published addressing this question (Table 3) ( Table 3) . Hospitalization accounts for two thirds of the cost pharmacological properties (Table 4) . Key pharmacological differences amongst b-adrenoceptor blockers include: relative of management of the heart failure patient [45] and therefore agents that can reduce hospitalization may impact favourably selectivity for the b 1 -and b 2 -adrenoceptor, possession of additional vasodilator properties, differential effects on beta on overall health care costs.
The overall primary end-point of the US Multicentre adrenoceptor up-regulation and a variety of ancillary properties. It is unclear at present which, if any, of these Carvedilol Study Program was in fact combined morbidity and mortality outcome, which was significantly reduced properties may be of substantial clinical significance. However, clinical and laboratory assessment of a number of with carvedilol therapy. The magnitude of the combined morbidity-mortality benefit was very similar in the Australia these agents permit some cautious observations to be made. The use of drugs that possess a vasodilator component & New Zealand study of patients with mild heart failure symptoms [39] , and again is consistent with observations may be useful in helping overcome the initial negative inotropy of the b-adrenoceptor blocking component of the made from smaller studies with the drug [27] .
drug. b-adrenoceptor blocker/vasodilators appear to be better tolerated than pure b-adrenoceptor blockers during Choice of b-adrenoceptor blocker in heart failure initiation [46] . It has been suggested by some that the vasodilator component rather than the b-adrenoceptor b-adrenoceptor blocking drugs are a heterogeneous therapeutic group with many individual agents possessing unique blocking component of these drugs underlies the drugs Table 4 Pharmacological properties of b-adrenoceptor blocking agents used in the management of heart failure. 
disappears during chronic therapy with drugs remains to be elucidated in further clinical studies. a-adrenoceptor blockade and b-adrenoceptor blockade in combination [47] .
Approach to management of the heart failure patient A more important pharmacological property may be that with b-adrenoceptor blockers agents such as carvedilol and bucindolol are relatively nonselective inhibitors of b 1 -vs b 2 -adrenoceptors. In heart Two decades of administration of b-adrenoceptor blockers to patients with heart failure has taught us much about how failure, there is selective b 1 -adrenoceptor down-regulation with relative preservation of b 2 -adrenoceptor density [5] to safely administer these agents to these patients. It is clear that the major difficulties with the use of these agents tend (relative percentages: b 1 80% vs b 2 20% in normal subjects compared with b 1 60% vs b 2 40% in CHF patients). If to occur during the initiation and uptitration phase of treatment. b-adrenoceptor blockers indeed act as a shield against the toxic effects of catecholamines on the myocardium, blockade
Overall about 50% of patients report worsening symptoms during the uptitration phase [55] , although this figure may of b 2 -adrenoceptors assumes greater significance.
Blockade of both receptor sub-types does not occur with be exacerbated by the concerns of the treating physician. Indeed, recent multicentre studies with these drugs confirm selective b 1 -selective drugs such as metoprolol and this may account for differing haemodynamic and neurohormonal a very high rate of adverse events occurring in both the placebo and active treatment groups [44] . Nevertheless, it is effects of these drugs [48] . Interestingly, one of the earliest studies to point towards a beneficial effect of b-adrenoceptor worth persisting with strategies to achieve target doses of b-adrenoceptor blockers, as patients who experience diffiblockers in heart failure was the Beta-blocker Heart Attack Trial (BHAT) [49] in post-myocardial infarction patients culties during uptitration are eventally conferred long-term clinical benefits similar to those who had no problems with heart failure. The beneficial effects seen in that study were with the prototype non-selective b-adrenoceptor during initiation [55] .
The two major problems during initiation are worsening blocker, propranolol.
b-adrenoceptor upregulation cannot explain the beneficial of underlying heart failure and, in patients receiving vasodilating b-adrenoceptor blockers, symptomatic postural effects observed with drugs such as carvedilol and bucindolol in heart failure. These drugs appear to possess a unique hypotension. In order to minimise the possibility of both problems occurring, it is important to ensure that, pharmacological property (guanine nucleotide modulatable binding [17] ) that prevents up-regulation from occurring. before initiation is attempted, patients are stable clinically and on stable doses of their concomitant medication. A Thus, the beneficial effects observed with these drugs (the magnitude of which is at least as great as with any other b-adrenoceptor blocking drug should not be administered to patients with unstable or decompensated heart failure. b-adrenoceptor blocker) occur in the absence of b-adrenoceptor up-regulation.
Very low doses of b-adrenoceptor blocker should be used at commencement e.g. 3.125 mg carvedilol or 6.25 mg Even in the presence of drugs that do cause adrenoceptor up-regulation (e.g metoprolol [16] ), the b-receptor is nearly metoprolol. The patient needs to be subsequently observed acutely for a few hours, then reviewed on a 1-to-2 weekly completely blocked at pharmacological doses of the drug and therefore putative improved inotropic effects that may basis whilst uptitrating the drug to target dosage. Despite these concerns, patients can generally be initiated in an result from upregulation of receptors and post-receptor activation of cyclic AMP would be blocked at the level of outpatient setting. Postural hypotension, if it is to occur, is generally seen the receptor [14] . In addition, the time course of improvement in ventricular function does not parallel that of early in patients receiving vasodilating b-adrenoceptor blockers. This can usually be effectively managed by pharmacological up-regulation achieved with drugs such as metoprolol. Adrenoceptor up-regulation occurs in vitro in temporarily reducing dose of concomitant ACE inhibitor and/or diuretic to permit establishment and uptitration of minutes to hours, whilst improvements in ventricular function take weeks to months. the b-adrenoceptor blocker. Another useful modification to therapy is to separate the b-adrenoceptor blocker and ACE Finally, some drugs possess ancillary properties that have been demonstrated in vitro and may turn out to be of great inhibitor dosage time by 3 h or greater to allow the vasodilator effects of one drug to wear off before the next clinical importance. For example, carvedilol possesses both anti-proliferative [50] and anti-oxidant [51] properties that drug is administered. If worsening heart failure occurs with b-adrenoceptor theoretically may play an important role in disease progression in heart failure. Heart failure is a state of increased blocker initiation, this can generally be treated by an increase in diuretic dose which usually permits stabilisation of the oxidative stress [52] and this may contribute to disease progression by stimulation of apoptosis (programmed cell condition. If necessary, a delay in scheduled uptitration of b-adrenoceptor blocker may be required. death). Furthermore, carvedilol uniquely inhibits endothelin-1 production from cultured endothelial cells [53] and Can we predict which patients will tolerate badrenoceptor blockers during initiation? It would be its effects appear to be independent of its b-adrenoceptor blocking, a-adrenoceptor blocking and anti-oxidant effects.
expected that patients most reliant upon sympathetic activation to maintain cardiac output, i.e. patients with Endothelin-1 is of major importance in disease progression in heart failure and plasma levels have been found to be a severe chronic heart failure, would be those with the greatest difficulties during initiation, however this has not as yet powerful independent marker of prognosis [54] .
effects on the biology of the adult mammalian cardiocyte. been definitively demonstrated [55] . The extreme elderly as have also been demonstrated, with a meta-analysis suggesting 14 Packer M. Pathophysiological mechanisms underlying the a mortality reduction of 30% when added to standard heart effects of b-adrenergic agonists and antagonists on functional failure therapies [56] . In addition, further mortality data are capacity and survival in chronic heart failure. Circulation 1990; being accumulated. These clinical data are underpinned by It has not been established whether these drugs are useful S105-S113.
in patients with asymptomatic left ventricular dysfunction. 
